Sana Biotechnology, Inc. Deferred Income Tax Expense (Benefit)
Sana Biotechnology, Inc. (SANA) reported Deferred Income Tax Expense (Benefit) of -$7.55 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-03-16.
Discontinued › Cash Flow
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2022-03-16
- Sana Biotechnology, Inc. deferred income tax expense (benefit) for fiscal 2019 was -$7.55M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2019-12-31 | -$7.55M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |